Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Condition(s) targeted: Malaria; Plasmodium Falciparum

Intervention: PfSPZ Challenge (Biological); Normal Saline (NS) (Biological)

Phase: Phase 1

Status: Completed

Sponsored by: Sanaria Inc.

Official(s) and/or principal investigator(s):
Robert Sauerwein, MD, Principal Investigator, Affiliation: Radboud University

The purpose of the study is to determine the safety and tolerability of ID administration of PfSPZ Challenge to volunteers taking chloroquine chemoprophylaxis (an approach called PfSPZ-CVac).

Official title: Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Frequency and magnitude of adverse events in study groups

Secondary outcome:

Presence of parasitemia after Pf CHMI as assessed by microscopy

Time to parasitemia after Pf CHMI as assessed by microscopy

Kinetics of parasitemia as assessed by qPCR

Detailed description: The study is a single centre, double blind, randomized controlled clinical trial. Volunteers, investigators and laboratory personnel will be blinded. A maximum of 30 volunteers will be randomly divided into four groups. All volunteers will receive standard weekly chloroquine chemoprophylaxis for a period of 14 weeks (98 days). During this period, groups 1 and 3 will receive six ID injections of PfSPZ Challenge, containing a total of 75,000 PfSPZ of the Pf NF54 strain, on days 8, 36 and 64 (immunizations 1, 2 and 3). The control groups 2 and 4 will receive ID injections with normal saline (NS) on the same days. Thirty-three days after the last dose of chloroquine, volunteers in groups 1 and 2 will have controlled human malaria infection (CHMI) by the bites of five mosquitoes infected with PfSPZ of the Pf NF54 strain. If ≥75% of volunteers in group 1 are protected against this homologous Pf CHMI, volunteers in groups 3 and 4 will have CHMI by the bites of five mosquitoes infected with the heterologous Pf NF135. C10 strain 75 days after the last dose of chloroquine. If <75% of volunteers in group 1 are protected against the homologous Pf CHMI, volunteers in groups 3 and 4 will receive an additional immunization (immunization 4), which will consist of six ID injections on the same day of 75,000 PfSPZ Challenge and NS respectively, at day 162. In this fourth immunization period chloroquine will be administered for another 6 weeks starting at day 154. Finally, 33 days after the last dose of chloroquine, volunteers in groups 3 and 4 will have homologous Pf CHMI by the bites of five PfSPZ-infected mosquitoes. After CHMI all volunteers will be treated with a curative regimen of Malarone® (each tablet containing 250 mg atovaquone and 100 mg proguanil), either at the time of detection of blood stage parasitemia or 21 days after exposure to PfSPZ-infected mosquitoes. Volunteers will be checked for parasites by thick smear at least twice after treatment.

If one of the volunteers is not fit to participate in the study on day - 1, an alternate

volunteer who passed screening will replace him or her. For this purpose 3 additional volunteers will be screened for possible back up.

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy volunteers (males or females) of ≥ 18 and ≤ 35 years of age

- Good health based on history and clinical examination (physical examination and

laboratory screening)

- Negative pregnancy test

- Use of adequate contraception for females

- Signing of the informed consent form, thereby demonstrating understanding of the

meaning and procedures of the study

- Agreement to inform the general practitioner and to sign a request to release medical

information concerning contraindications for participation in the study

- Willingness to undergo administration of PfSPZ Challenge by needle and syringe and

willingness to undergo challenge by mosquito bites

- For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the

trial centre or living in Nijmegen with a third party that could contact the clinicians in case of alteration of consciousness during a part of the study (day 5 after challenge until treatment is finished)

- Reachable (24/7) by mobile phone during the whole study period

- For volunteers living in Nijmegen: living with a third party that could contact the

clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial centre during a part of the study (day 5 after challenge until treatment is finished)

- Available to attend all study visits

- Agreement to refrain from blood donation to Sanquin or for other purposes, during the

whole study period

- Willingness to undergo HIV, hepatitis B and hepatitis C tests

- Negative urine toxicology screening test at screening visit and the day before

challenge

- Willingness to take a prophylactic regime of chloroquine and a curative regimen of

Malarone®

- Willingness to undergo ophthalmologic examination after passing all other inclusion

criteria Exclusion Criteria:

- History of malaria

- Plans to travel to malaria endemic areas during the study period

- Plans to travel outside of the Netherlands during the challenge period

- Previous participation in any malaria vaccine study and/or positive serology for Pf

- Symptoms, physical signs and laboratory values suggestive of systemic disorders

including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers

- History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)

- History of arrhythmias or prolonged QT-interval

- Positive family history of 1st and/or 2nd degree relatives who experienced cardiac

events when < 50 years old

- An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by

the Systematic Coronary Risk Evaluation (SCORE) system

- Clinically significant abnormalities in electrocardiogram (ECG) at screening

- Body Mass Index (BMI) below 18 or above 30 kg/m2

- Any clinically significant deviation from the normal range in biochemistry or

haematology blood tests

- Positive HIV, HBV or HCV tests

- Participation in any other clinical study within 30 days prior to the onset of the

study

- Enrolment in any other clinical study during the study period

- For women: pregnancy or lactation

- Volunteers unable to give written informed consent

- Volunteers unable to be closely followed for social, geographic or psychological

reasons

- History of drug or alcohol abuse interfering with normal social function during a

period of one year prior to enrolment in the study

- A history of psychiatric disease

- A history of convulsions

- Known hypersensitivity to Malarone® or chloroquine

- The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying

drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period

- Contraindications to Malarone® or chloroquine including treatment taken by the

volunteer that interferes with Malarone® or chloroquine

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including

asplenia

- Co-workers or trainees of the departments of Medical Microbiology or Internal

Medicine of the RUNMC

- Known history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia

trait or G6PD deficiency. If there is any suspicion of G6PD deficiency (based on

medical history during screening or ethnic background - Mediterranean, African, or

Asian), we will assess G6PD status of that particular subject before inclusion.

- Abnormalities during ophthalmologic examination

Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB, Netherlands

Starting date: September 2012
Last updated: May 14, 2014